Plain-English Summary

Semaglutide CUD EHR studied semaglutide in EHR cohorts of patients with obesity or type 2 diabetes. Semaglutide was associated with lower risk of incident and recurrent cannabis use disorder diagnosis and recurrent CUD diagnosis in matched cohorts.

Key Findings

• Semaglutide was associated with lower risk of incident and recurrent cannabis use disorder diagnosis and recurrent CUD diagnosis in matched cohorts.
• Authors called for further preclinical and randomized clinical studies.

Limitations

• Observational data cannot establish causality.
• Outcome was diagnosis/encounter-based.
• Some subgroup results were not uniformly significant.

Why It Matters

Semaglutide was associated with lower risk of incident and recurrent cannabis use disorder diagnosis and recurrent CUD diagnosis in matched cohorts.

Viral Vitalism Verdict

Useful evidence, bounded by design: Observational data cannot establish causality.

Sources

1. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations - Molecular Psychiatry